Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery

Huang, Zhengwei; Huang, Ying; Wang, Wenhua; Fu, Fangqin; Dang, Shishuai; Li, Cheng; Ma, Cheng; Zhang, Xuejuan; Zhao, Ziyu; Pan, Xin; Wu, Chuanbin

doi:10.1016/j.jconrel.2020.06.004

Cited by 37 publications

(22 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhaled radiolabelled SLNs biodistribution showed significant uptake in lymphatics, with a high rate of distribution in periaortic, axillary, and inguinal lymph nodes and these findings indicate that SLNs may have the potential to be efficient carriers for lymphoscintigraphy or pulmonary therapy [ 28 ]. Besides, some SLNs may remain mostly intact in the pulmonary area, which may lead to longer lung retention times [ 177 ].…”

Section: Inhalable Anticancer Drug-loaded Lipid-based Nanocarriersmentioning

confidence: 99%

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

et al. 2021

View full text Add to dashboard Cite

Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment.

show abstract

Section: Inhalable Anticancer Drug-loaded Lipid-based Nanocarriersmentioning

confidence: 99%

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some researchers revealed that the lung retention time was proportional to this particle size. 52 Additionally, the enhanced targeting ability of the PM-NPs was demonstrated by the distribution of the DiIlabeled nanoparticles. As shown in Figure 6E, more red fluorescence signals could be observed in the frozen tumor slices of mice treated with the PM-NPs than in those treated with the NPs.…”

Section: In Vivo Tumor Targeting Capability Of Pm-npsmentioning

confidence: 99%

<p>Platelet-Mimicking Drug Delivery Nanoparticles for Enhanced Chemo-Photothermal Therapy of Breast Cancer</p>

Pei¹,

Huang²,

Chen³

et al. 2020

IJN

View full text Add to dashboard Cite

Background Traditional nanoparticle-based drug delivery systems suffer from several limitations, such as easy clearance from blood and inaccurate targeting. Materials and Methods Here, we developed platelet membrane-coated nanoparticles (PM-NPs) to improve the precise delivery of drugs to tumor sites and enable a more efficient photothermal therapy (PTT) treatment. Results Mimicking the natural platelet membrane, nanoparticles containing drugs and photothermal agents were not recognized and cleared by the immune system; they could circulate in the blood for a long time and accumulate more efficiently at the tumor site, thus releasing more antitumor drugs and achieving better PTT effects. It is worth mentioning that, in this study, we found that tumors in mice treated with the platelet-mimicking nanoparticles were completely eliminated without recurrence during the observation period (up to 18 days). Conclusion This study provides a new strategy to design delivery systems of drugs or photothermal agents, whether in biotherapy or other fields.

show abstract

“…Although Huang et al . [ 110 ] and Kreyling et al . [ 111 ] reported positive correlation between the nanoparticle size and lung retention time, Anderson et al .…”

Section: Potential Challenges For Clinical Translation Of Nanoparticlesmentioning

confidence: 99%

Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential

Vichare

Janjić

2022

Inflammation

View full text Add to dashboard Cite

— Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by progressive lung impairment typically triggered by inflammatory processes. The mortality toll for ARDS/ALI yet remains high because of the poor prognosis, lack of disease-specific inflammation management therapies, and prolonged hospitalizations. The urgency for the development of new effective therapeutic strategies has become acutely evident for patients with coronavirus disease 2019 (COVID-19) who are highly susceptible to ARDS/ALI. We propose that the lack of target specificity in ARDS/ALI of current treatments is one of the reasons for poor patient outcomes. Unlike traditional therapeutics, nanomedicine offers precise drug targeting to inflamed tissues, the capacity to surmount pulmonary barriers, enhanced interactions with lung epithelium, and the potential to reduce off-target and systemic adverse effects. In this article, we focus on the key cellular drivers of inflammation in ARDS/ALI: macrophages. We propose that as macrophages are involved in the etiology of ARDS/ALI and regulate inflammatory cascades, they are a promising target for new therapeutic development. In this review, we offer a survey of multiple nanomedicines that are currently being investigated with promising macrophage targeting potential and strategies for pulmonary delivery. Specifically, we will focus on nanomedicines that have shown engagement with proinflammatory macrophage targets and have the potential to reduce inflammation and reverse tissue damage in ARDS/ALI. Graphical abstract

show abstract

Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery

Cited by 37 publications

References 78 publications

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

<p>Platelet-Mimicking Drug Delivery Nanoparticles for Enhanced Chemo-Photothermal Therapy of Breast Cancer</p>

Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential

Contact Info

Product

Resources

About